---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-23-000015"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T01:16:35.937371+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q4 2022 revenue down 25% to $12.6M; net loss $6.0M; guides 2023 rev $58-61M

## Summary
- Q4 total revenue $12.6M (-25% YoY); Advanced Energy segment $10.5M (-30% YoY); OEM $2.1M (+15% YoY).
- FY2022 net loss $23.2M ($0.67/share) vs $15.2M in 2021; adjusted EBITDA loss $15.4M vs $8.8M.
- Introduces FY2023 guidance: total revenue $58-61M (30-37% growth); net loss ~$14M vs $23.2M in 2022.
- Post-quarter: FDA 510(k) clearance for Renuvion APR Handpiece (Feb 27); $35M credit facility with MidCap Financial.
- CEO cites FDA Safety Communication disruption; expects >35% Advanced Energy growth in 2023.

## SEC filing metadata
- accession: 0000719135-23-000015
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/apyx-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-23-000015
- JSON: https://secwatch.observer/filing/0000719135-23-000015.json
- Plain text: https://secwatch.observer/filing/0000719135-23-000015.txt

## Key facts
- Earnings Releases
  Apyx Medical Corp reported full year ended December 31, 2022 results: revenue $44.5 million, net income Net loss attributable to stockholders of $23.2 million. Guidance initiated.
  - Period: full year ended December 31, 2022
  - Revenue: $44.5 million
  - Net income: Net loss attributable to stockholders of $23.2 million
  - Guidance: initiated
  - Result: reported results
  source text: the fourth quarter of 2021. • Adjusted EBITDA loss of $4.1 million, compared to $0.3 million for the fourth quarter of 2021. Full Year 2022 Financial Summary: • Total revenue of $44.5 million, down 8% year-over-year. ◦ Advanced Energy revenue of $36.8 million, down 14% year-over-year. ◦ OEM revenue of $7.7 million, up 39% year-over-year. • Net loss attributable to
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm
- Earnings Releases
  Apyx Medical Corp reported for the fourth quarter and year ended December 31, 2022 results: revenue $12.6 million, net income Net loss attributable to stockholders of $6.0 million.
  - Period: for the fourth quarter and year ended December 31, 2022
  - Revenue: $12.6 million
  - Net income: Net loss attributable to stockholders of $6.0 million
  - Result: reported results
  source text: full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023. Fourth Quarter 2022 Financial Summary : • Total revenue of $12.6 million, down 25% year-over-year. ◦ Advanced Energy revenue of $10.5 million, down 30% year-over-year. ◦ OEM revenue of $2.1 million, up 15% year-over-year. • Net loss attributable to
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913523000015/0000719135-23-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.